From The Editor | November 18, 2026

Scaling Personalization: Inside The Manufacturing & Analytical Hurdles Of mRNA Cancer Immunotherapies

ARW Edit Headshot 2

By Anna Rose Welch, Editorial & Community Director, Advancing RNA

Leadership, strength-GettyImages-2249283142

A few months ago, I had the immense pleasure of moderating a panel at the CPI/BIA/Imperial College London RNA Vaccines & Therapeutics conference in London. Given the U.K.’s work with personalized mRNA cancer immunotherapies via the NHS’ Cancer Vaccine Launch Pad, I thought it was an important time — and venue — to have a discussion on what the UK has learned thus far and where the nation is facing growing pains in scaling this increasingly important application for mRNA technology. I was thrilled to be joined on stage by several luminaries in the mRNA world who helped me parse out where the greatest sticking points exist: the Cancer Vaccine Launch Pad’s Dr. Lennard Lee; Wellcome Leap’s Parker Moss; MHRA’s Andreea Iftimia-Mander; and CPI’s Juliana Haggerty.

As I wrote in part 1 of this two-part article series, I was particularly inspired by a quote from panelist Dr. Lee: “If you want to feed a family, give them a fish. But if you want to empower them — in this case, if you want to empower the entire cancer research system in the UK to advance across the world — you need to give them a boat and a fishing rod.”

In part 1, I argued that, to help our boat float much more buoyantly, we need to learn more about the basic biology of our products — especially as we start seeing mRNA products succeed clinically in some cases (i.e., Moderna/Merck’s melanoma product) while not in others (i.e., BioNTech’s colorectal cancer product). But as we also know from the autologous cell therapies that have come before us, manufacturing and scaling personalized products is no mean feat, and there are a handful of efforts we need to be tackling today to realize a more efficient and (ideally) decentralized manufacturing process.

Fortunately for us, the panel had a few ideas on what it will take to make our analytical development and manufacturing more efficient processes.

From Biopsy to Bedside in Six Days: Re-Engineering the Personalized mRNA Workflow

We often tout the efficiency of mRNA manufacturing compared to autologous cell therapy (or any other cell-based) manufacturing. However, when it comes to personalized manufacturing, we still have quite a way to go to achieve our ideal turn-around. Moss did a particularly nice job of summarizing what he hopes our more efficient future will look like:

“We need a standardized process: If there’s a biopsy on Friday, we need to carry out sequencing on Monday, DNA template production on Tuesday; IVT & formulation on Wednesday; and QP release and delivery to the patient on Thursday.”

Though we’re nowhere near making this a reality, that’s not to say we haven’t made progress as far as manufacturing is concerned. As Haggerty went on to explain, we are seeing some incredible improvements in manufacturing — in part, thanks to the work being done in the UK via CPI’s RNA Biofoundry. While batch processing used to necessitate a more leisurely, sequential development paradigm with (for example) purification occurring one week, followed by encapsulation the following week, Biofoundary is unlocking same-day purification and encapsulation.

However, progress in one area simply shifts focus to another area that needs to be improved upon — for example, DNA supply. As an industry, we’re no stranger to development silos. In turn, as Haggerty emphasized, we need to be thinking about the entire process from end-to-end, rather than simply optimizing our own individual pieces of the puzzle.

“Once we improve on one thing, suddenly we have to focus on another bit,” Haggerty admitted. “I think we need collectively to be working on speeding up each step of the process at the same time.”

There are, of course, innovations we’re working on as a space that will improve manufacturing turn-around time. She referenced, for example, the promise of on-site enzymatic synthesis to speed up DNA production, while Moss referred to the R3G Biofoundry Program, a partnership established between the UK and the Singapore governments to replace bioreactor manufacturing with continuous microfluidic manufacturing. Similarly, the rise of modular manufacturing has enabled companies to scale-out and perform manufacturing tasks in parallel.  

However, “I do think there is more than one way to accomplish manufacturing in parallel,” Haggerty added. “If you’re able to move much faster, you can also do things in a staggered way. This is how we’re starting to run things at Biofoundry. We don’t run from sequencing DNA all the way through, then start the next product. Rather, we start DNA manufacturing, then once that equipment is free, we can start a second DNA synthesis while the first product moves on to RNA production. This allows us a degree of parallelization.”

As she went on to clarify, though this staggered approach improves development speed, this does place greater pressure on tech vendors and suppliers to provide solutions to help track and manage data from each batch. Greater manufacturing efficiency also places a great deal of pressure on us to reduce single-use waste we’re likely to generate upon scaling out to thousands of patients.

“It’s one thing when we’re talking about tens of patients,” Haggerty added. “But if you’re talking about single-use filters, columns, and cartridges scaled to thousands of individual patients, that’s mountains of waste. That is also a challenge we need to be thinking about today.”

Improving Analytical Development: Tackling Release Testing and Standardization Hurdles

Two years ago, I was privy to a conversation on personalized medicines development that emphasized just what we’re up against — particularly analytically — in targeting larger oncological indications like melanoma and pancreatic cancer. As one expert at the time clarified, treating 2-3 percent of the pancreatic cancer population with a personalized immunotherapy would equate to working with 10,000 unique RNAs — or 20,000 batches (DS & DP) analytically speaking.

Therefore, it should come as no surprise that analytical development garnered more airtime during this most recent discussion in London. As part 1 explained, we’ve gotten increasingly better at scrutinizing our CQAs using a suite of nifty analytical tools. What these measurements/data tell us about the function of our molecules, however, remains fuzzy.

In addition to the unknowns of our structure/function relationship, release assays remain a particular growing pain in personalized development.

“QC testing followed by QP review and release requires a huge amount of time and resources,” Haggerty said. While the future is brightened by the prospect of PAT, online monitoring, and real-time release, we’re still a long way from realizing these technologies today. Though we certainly can parallelize assays and use high-throughput automation today, Haggerty is particularly excited by the prospect of multiplex assays that can give us information about multiple attributes with one single assay.

Not surprisingly, NGS received numerous shout-outs during this discussion — with the caveat that validation remains a challenge.

“Validation turns into a different type of validation — an information-rich analysis — which begs the question: How can we interpret what NGS is telling us in a consistent way?” she asked.

This is ultimately where the development of standards comes in. As Iftimia-Mander shared, MHRA is currently developing NGS standards, as well as working with NIST on a round-robin study analyzing mRNA and determining which method(s) can be standardized today. She has also been part of consortia striving to garner funding to standardize process, analytics, QC release, and potency.

“Standardization is the missing link that can show batch-to-batch, lab-to-lab, or manufacturing site-to-manufacturing site that every batch of this product is manufactured consistently, performs the same biologically, and has the same safety profile,” Iftimia-Mander said.

But as she went on to say, though standardization is incredibly important for the longevity and efficiency of the industry, funding remains a big barrier. Given the UK’s increasing focus on engineering biology, Iftimia-Mander does see opportunities to influence policy and to garner funding from the engineering biology world — especially because cell therapies and mRNA therapies “fit quite nicely under this umbrella,” she explained.

The rest of the panel also pointed to the funding benefits that can come from continued development experience and clinical data in the cancer immunotherapy realm.

As Lee nicely concluded, “Cancer immunotherapies are included in the National Cancer Plan for England. If you look at industrial strategy, cancer immunotherapies are in there. If you look at the science strategy, cancer immunotherapies are in there. So, though it may be easier said than done, the simple message is: Go do research on cancer vaccines because it aligns with national strategy and as more projects move forward, more funding will happen.”